Physician profile
Scott E Schmidt
NPI 1609889336
$1,391.67
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.11 · 2020: $334 · 2021: $496 · 2022: $357 · 2023: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $105.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $331.80 | 2021-2023 | Vraylar |
| Gilead Sciences, INC. | $328.11 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $176.37 | 2020-2021 | |
| Alkermes, INC. | $148.58 | 2019-2022 | |
| Eisai INC. | $75.74 | 2020 | |
| Indivior INC. | $67.30 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $30.20 | 2019 | |
| Neurocrine Biosciences, INC. | $27.59 | 2021 | |
| Heron Therapeutics, INC. | $22.92 | 2022 | |
| Dermira, INC. | $20.62 | 2020 | |
| Janssen Pharmaceuticals, INC | $19.74 | 2022 | |
| Corium, LLC | $18.66 | 2022 | |
| Orexo US, INC. | $18.44 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.64 | 2021 | |
| Abbott Laboratories | $16.00 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $14.74 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.63 | 2021 | |
| Bausch Health US, LLC | $14.51 | 2022 | |
| Novo Nordisk INC | $14.20 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.